TWI227274B - Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same - Google Patents
Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same Download PDFInfo
- Publication number
- TWI227274B TWI227274B TW88109144A TW88109144A TWI227274B TW I227274 B TWI227274 B TW I227274B TW 88109144 A TW88109144 A TW 88109144A TW 88109144 A TW88109144 A TW 88109144A TW I227274 B TWI227274 B TW I227274B
- Authority
- TW
- Taiwan
- Prior art keywords
- virus
- deactivated
- japanese encephalitis
- vaccine
- particle
- Prior art date
Links
- 241000710843 Japanese encephalitis virus group Species 0.000 title claims abstract description 20
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 30
- 230000002163 immunogen Effects 0.000 title abstract description 27
- 230000008569 process Effects 0.000 title description 2
- 229940031551 inactivated vaccine Drugs 0.000 title 1
- 241000700605 Viruses Species 0.000 claims abstract description 128
- 239000002245 particle Substances 0.000 claims abstract description 72
- 238000004519 manufacturing process Methods 0.000 claims abstract description 46
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 8
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 8
- 229960005486 vaccine Drugs 0.000 claims description 82
- 102000036639 antigens Human genes 0.000 claims description 38
- 108091007433 antigens Proteins 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 36
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 24
- 210000004556 brain Anatomy 0.000 claims description 19
- 230000003472 neutralizing effect Effects 0.000 claims description 18
- 238000000746 purification Methods 0.000 claims description 18
- 238000004113 cell culture Methods 0.000 claims description 15
- 230000009849 deactivation Effects 0.000 claims description 15
- 210000002845 virion Anatomy 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 7
- 230000008105 immune reaction Effects 0.000 claims description 6
- 238000000053 physical method Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 claims 2
- 101000819297 Mus musculus Glucose-6-phosphate isomerase Proteins 0.000 claims 1
- 230000036046 immunoreaction Effects 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 229940028617 conventional vaccine Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 77
- 241000699670 Mus sp. Species 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 13
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 9
- 201000005807 Japanese encephalitis Diseases 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 239000012888 bovine serum Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 6
- 238000005199 ultracentrifugation Methods 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 229940031416 bivalent vaccine Drugs 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 241000272814 Anser sp. Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 229940124868 Japanese encephalitis virus vaccine Drugs 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010049190 Red blood cell agglutination Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 229960003239 encephalitis vaccine Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31976298 | 1998-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI227274B true TWI227274B (en) | 2005-02-01 |
Family
ID=18113906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW88109144A TWI227274B (en) | 1998-10-05 | 1999-06-02 | Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6841374B1 (enExample) |
| EP (1) | EP1057889B1 (enExample) |
| JP (2) | JP4371343B2 (enExample) |
| KR (1) | KR20010032699A (enExample) |
| CN (2) | CN1618464A (enExample) |
| AU (1) | AU743546B2 (enExample) |
| CA (1) | CA2311336C (enExample) |
| MY (1) | MY126520A (enExample) |
| TW (1) | TWI227274B (enExample) |
| WO (1) | WO2000020565A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10144906B4 (de) * | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| US7060280B2 (en) * | 2003-06-11 | 2006-06-13 | Academia Sinica | Immunization against flavivirus |
| US7780027B2 (en) * | 2007-02-08 | 2010-08-24 | Michael Coady | Axially stacked double barrel animal feeder system |
| SG10201404101RA (en) | 2007-08-28 | 2014-09-26 | Baxter Int | Method For Producing Viral Vaccines |
| MY173418A (en) | 2007-12-26 | 2020-01-23 | Daiichi Sankyo Co Ltd | Method of producing japanese encephalitis avccines stably storable over long time and use of the vaccine |
| JP5511660B2 (ja) | 2008-06-04 | 2014-06-04 | 一般財団法人化学及血清療法研究所 | 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法 |
| CN101333246B (zh) * | 2008-07-30 | 2011-04-13 | 中国农业科学院哈尔滨兽医研究所 | 乙型脑炎病毒e蛋白中和性b细胞抗原表位多肽及其应用 |
| US8961994B2 (en) * | 2008-11-17 | 2015-02-24 | Vgx Pharmaceuticals, Llc | DNA constructs eliciting immune response against flavivirus and effective adjuvants |
| WO2010137036A2 (en) * | 2009-05-25 | 2010-12-02 | Panacea Biotec Ltd | Novel japanese encephalitis vaccine and method of manufacturing the same |
| CN101792741A (zh) * | 2010-04-07 | 2010-08-04 | 西北农林科技大学 | 表达jev免疫原基因的重组杆状病毒及其制备和应用 |
| JP6963460B2 (ja) * | 2016-10-27 | 2021-11-10 | 一般財団法人阪大微生物病研究会 | たん白質の定量方法 |
| WO2021161390A1 (ja) * | 2020-02-10 | 2021-08-19 | 花王株式会社 | ヒトノロウイルス不活化評価法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6147185A (ja) * | 1984-08-09 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 日本脳炎ウイルスの精製方法 |
| JPS6153227A (ja) | 1984-08-23 | 1986-03-17 | Biseibutsu Kagaku Kenkyusho:Kk | 日本脳炎・豚パルボウイルス感染症混合生ワクチン |
| US5719051A (en) * | 1989-12-22 | 1998-02-17 | Immuno Aktiengesellschaft | Perfusion system and a method for the large scale production of virus or virus antigen |
| AT393356B (de) * | 1989-12-22 | 1991-10-10 | Immuno Ag | Verfahren zur herstellung von fsme-virus-antigen |
| JPH07265093A (ja) | 1994-03-30 | 1995-10-17 | Chemo Sero Therapeut Res Inst | 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法 |
| DE69626022T3 (de) | 1995-08-01 | 2008-05-08 | Sanofi Pasteur | Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff |
| US6207439B1 (en) * | 1997-03-25 | 2001-03-27 | Center For Disease Control | Purification of Japanese encephalitis virus |
| US5891705A (en) | 1997-04-08 | 1999-04-06 | Pentose Pharmaceuticals, Inc. | Method for inactivating a virus |
| CN1142271C (zh) | 1997-08-28 | 2004-03-17 | 第一制糖株式会社 | 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗 |
-
1999
- 1999-06-02 KR KR1020007005984A patent/KR20010032699A/ko not_active Ceased
- 1999-06-02 EP EP99923858A patent/EP1057889B1/en not_active Expired - Lifetime
- 1999-06-02 AU AU40578/99A patent/AU743546B2/en not_active Ceased
- 1999-06-02 JP JP2000574663A patent/JP4371343B2/ja not_active Expired - Lifetime
- 1999-06-02 CN CNA2004100473162A patent/CN1618464A/zh active Pending
- 1999-06-02 US US09/555,704 patent/US6841374B1/en not_active Expired - Fee Related
- 1999-06-02 CA CA 2311336 patent/CA2311336C/en not_active Expired - Fee Related
- 1999-06-02 TW TW88109144A patent/TWI227274B/zh not_active IP Right Cessation
- 1999-06-02 WO PCT/JP1999/002931 patent/WO2000020565A1/ja not_active Ceased
- 1999-06-02 CN CNB998017647A patent/CN1160454C/zh not_active Expired - Fee Related
- 1999-06-03 MY MYPI99002242A patent/MY126520A/en unknown
-
2009
- 2009-07-08 JP JP2009162261A patent/JP5095685B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1160454C (zh) | 2004-08-04 |
| JP4371343B2 (ja) | 2009-11-25 |
| US6841374B1 (en) | 2005-01-11 |
| EP1057889B1 (en) | 2009-04-22 |
| CN1287573A (zh) | 2001-03-14 |
| JP5095685B2 (ja) | 2012-12-12 |
| WO2000020565A1 (en) | 2000-04-13 |
| CN1618464A (zh) | 2005-05-25 |
| MY126520A (en) | 2006-10-31 |
| EP1057889A4 (en) | 2002-01-23 |
| CA2311336A1 (en) | 2000-04-13 |
| CA2311336C (en) | 2007-01-02 |
| AU4057899A (en) | 2000-04-26 |
| KR20010032699A (ko) | 2001-04-25 |
| EP1057889A1 (en) | 2000-12-06 |
| AU743546B2 (en) | 2002-01-31 |
| JP2009225809A (ja) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5095685B2 (ja) | 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法 | |
| FI117513B (fi) | Menetelmä PRRS-viruksen viljelemiseksi ja sen käyttö rokotteissa | |
| TWI688652B (zh) | 作為對抗腸病毒感染之免疫原的病毒顆粒及其製造 | |
| JP5264843B2 (ja) | 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス | |
| AU9004798A (en) | An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine | |
| CN102107003A (zh) | 一种猪繁殖与呼吸综合症病毒体疫苗及其制备方法 | |
| CN104293741A (zh) | 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用 | |
| CN102107004A (zh) | 一种猪繁殖与呼吸综合症病毒样颗粒疫苗及其制备方法 | |
| CN103007273A (zh) | 一种口蹄疫基因工程混合表位疫苗及其制备方法 | |
| CN108853490A (zh) | 一种预防手足口病和甲型肝炎的联合疫苗及其制备方法 | |
| CN103571798B (zh) | 鸭坦布苏病毒弱毒株及其应用 | |
| WO2022141266A1 (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
| CN116059337A (zh) | 新型佐剂重组带状疱疹疫苗及其制备与应用 | |
| CN1209837A (zh) | 用于轮状病毒感染的轮状病毒属抗原、疫苗和诊断试剂以及用于产生抗原的方法 | |
| EP2075005B1 (en) | Ipv-dpt vaccine | |
| JPWO2000020565A1 (ja) | 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法 | |
| Tanaka et al. | Bovine Adenovirus I. Recovery of a Serotype, Nagano, from Japanese Cattle4 | |
| JP4053587B2 (ja) | 不活性化レスピラトリーシンシシャルウイルスワクチン | |
| RU2699671C1 (ru) | Вакцина для ранней защиты против ящура типа О инактивированная эмульсионная | |
| CN116286679B (zh) | 一株经分离得到的猪流行性腹泻病毒变异株及其应用 | |
| CN106215185A (zh) | 一种禽呼肠孤病毒多联亚单位疫苗的制备方法 | |
| RU2665849C1 (ru) | Вакцина инактивированная эмульсионная против ящура типа О | |
| WO2024125100A1 (zh) | 一种ev71-ca16二价灭活疫苗及其制备方法和应用 | |
| JPH03135923A (ja) | 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン | |
| JPS60248179A (ja) | 家禽アデノウイルス２型の増殖方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |